TY - JOUR
T1 - A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus
AU - Dejnirattisai, Wanwisa
AU - Wongwiwat, Wiyada
AU - Supasa, Sunpetchuda
AU - Zhang, Xiaokang
AU - Dai, Xinghong
AU - Rouvinsky, Alexander
AU - Jumnainsong, Amonrat
AU - Edwards, Carolyn
AU - Quyen, Nguyen Than Ha
AU - Duangchinda, Thaneeya
AU - Grimes, Jonathan M.
AU - Tsai, Wen Yang
AU - Lai, Chih Yun
AU - Wang, Wei Kung
AU - Malasit, Prida
AU - Farrar, Jeremy
AU - Simmons, Cameron P.
AU - Zhou, Z. Hong
AU - Rey, Felix A.
AU - Mongkolsapaya, Juthathip
AU - Screaton, Gavin R.
N1 - Publisher Copyright:
© 2015 Nature America, Inc.
PY - 2015/1/16
Y1 - 2015/1/16
N2 - Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.
AB - Dengue is a rapidly emerging, mosquito-borne viral infection, with an estimated 400 million infections occurring annually. To gain insight into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a previously unknown epitope, the envelope dimer epitope (EDE), that bridges two envelope protein subunits that make up the 90 repeating dimers on the mature virion. The mAbs to EDE were broadly reactive across the dengue serocomplex and fully neutralized virus produced in either insect cells or primary human cells, with 50% neutralization in the low picomolar range. Our results provide a path to a subunit vaccine against dengue virus and have implications for the design and monitoring of future vaccine trials in which the induction of antibody to the EDE should be prioritized.
UR - http://www.scopus.com/inward/record.url?scp=84922947115&partnerID=8YFLogxK
U2 - 10.1038/ni.3058
DO - 10.1038/ni.3058
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25501631
AN - SCOPUS:84922947115
SN - 1529-2908
VL - 16
SP - 170
EP - 177
JO - Nature Immunology
JF - Nature Immunology
IS - 2
ER -